National Research (NASDAQ: NRCIA) is one of 2 publicly-traded companies in the “Business Support Services – NEC” industry, but how does it compare to its competitors? We will compare National Research to similar businesses based on the strength of its earnings, analyst recommendations, institutional ownership, valuation, risk, dividends and profitability.
Valuation & Earnings
This table compares National Research and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|National Research||$109.38 million||$20.51 million||39.83|
|National Research Competitors||$649.95 million||$22.08 million||26.67|
This is a summary of current ratings for National Research and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|National Research Competitors||3||19||14||1||2.35|
National Research presently has a consensus price target of $44.00, suggesting a potential upside of 25.53%. As a group, “Business Support Services – NEC” companies have a potential upside of 36.23%. Given National Research’s competitors stronger consensus rating and higher possible upside, analysts plainly believe National Research has less favorable growth aspects than its competitors.
National Research pays an annual dividend of $0.40 per share and has a dividend yield of 1.1%. National Research pays out 45.5% of its earnings in the form of a dividend. As a group, “Business Support Services – NEC” companies pay a dividend yield of 1.1% and pay out 45.5% of their earnings in the form of a dividend.
Risk and Volatility
National Research has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, National Research’s competitors have a beta of 1.72, meaning that their average stock price is 72% more volatile than the S&P 500.
This table compares National Research and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|National Research Competitors||10.56%||24.05%||13.04%|
Institutional & Insider Ownership
25.2% of National Research shares are owned by institutional investors. Comparatively, 56.1% of shares of all “Business Support Services – NEC” companies are owned by institutional investors. 37.5% of National Research shares are owned by insiders. Comparatively, 20.7% of shares of all “Business Support Services – NEC” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
National Research competitors beat National Research on 8 of the 13 factors compared.
National Research Company Profile
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions and physician engagement. NRC Health partners with clients across the range of healthcare services. The Company’s clients range from integrated health systems and post-acute providers, such as home health, long-term care and hospice, to payer organizations. NRC Health’s portfolio of solutions is designed to help healthcare companies.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.